Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.68 |
| ▸ | PPARG | P37231 | 15/20 | 0.68 |
| ▸ | PPARD | Q03181 | 4/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819439 | 0.90 | PPARA (0.55) | PPARAPPARGFFAR4 | |
| SCHEMBL6820298 | 0.87 | PPARA (0.52) | PPARAPPARGFFAR4 | |
| SCHEMBL6824551 | 0.82 | PPARA (0.48) | PPARAPPARGFFAR4 | |
| SCHEMBL29561793 | 0.81 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL3863004 | 0.81 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL6183795 | 0.78 | PPARG (0.71) | PPARAPPARG | |
| SCHEMBL6183969 | 0.77 | PPARG (0.72) | PPARAPPARG | |
| SCHEMBL6183260 | 0.75 | PPARG (0.56) | PPARAPPARG | |
| SCHEMBL6184321 | 0.74 | PPARG (0.60) | PPARAPPARG | |
| SCHEMBL6188420 | 0.74 | PPARG (0.61) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259494-A4 | ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1259494-A1 | ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060807-A1 | ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO. INC. (US) | 2001-08-23 | — | — | WO | disclosed |